Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: Pharmacometabolomics-informed pharmacogenomics

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 1, 2011, Pages 97-104

  Ji, Y ^a   Hebbring, S ^a   Zhu, H ^b   Jenkins, G D ^c   Biernacka, J ^c   Snyder, K ^c   Drews, M ^c   Fiehn, O ^d   Zeng, Z ^b   Schaid, D ^c   Mrazek, D A ^c   Kaddurah Daouk, R ^e   Weinshilboum, R M ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOMETHYLTRANSFERASE; ASPARAGINE; ASPARTIC ACID; CITALOPRAM; CLEAVAGE SYSTEM PROTEIN H; DIHYDROLIPOAMIDE DEHYDROGENASE; DRUG METABOLITE; ESCITALOPRAM; GLUTAMIC ACID; GLYCINE; GLYCINE DEHYDROGENASE; GLYCINE HYDROXYMETHYLTRANSFERASE; GLYCINE HYDROXYMETHYLTRANSFERASE 1; GLYCINE HYDROXYMETHYLTRANSFERASE 2; HYDROXYLAMINE; PROTEIN; SERINE; TETRAHYDROFOLIC ACID; UNCLASSIFIED DRUG;

AMINO ACID BLOOD LEVEL; AMINO ACID SYNTHESIS; ARTICLE; CONTROLLED STUDY; DEGRADATION; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; HAPLOTYPE MAP; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; METABOLOMICS; NITROGEN METABOLISM; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; QUICK INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY SCORE; REMISSION; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

BIOMARKERS, PHARMACOLOGICAL; CELL LINE; CHROMOSOMES, HUMAN, PAIR 9; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DNA-BINDING PROTEINS; DRUG MONITORING; FEMALE; GENETIC ASSOCIATION STUDIES; GLYCINE; GLYCINE DEHYDROGENASE (DECARBOXYLATING); HUMANS; INTRONS; LINKAGE DISEQUILIBRIUM; MALE; METABOLOME; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; SEROTONIN UPTAKE INHIBITORS;

EID: 78650513748     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.250     Document Type: Article

References (39)

1. Kessler, R.C. et al.; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289, 3095-3105 (2003).
2. Preskorn, S., Staga, C., Feighner, J. & Ross, R. (eds.). Antidepressants: Past, Present and Future (Springer, Berlin, Germany, 2004).
3. Thase, M.E. et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J. Clin. Psychiatry 66, 974-981 (2005).
4. Kaddurah-Daouk, R., Kristal, B.S. & Weinshilboum, R.M. Metabolomics: a global biochemical approach to drug response and disease. Annu. Rev. Pharmacol. Toxicol. 48, 653-683 (2008).
5. Schmidt, C. Metabolomics takes its place as latest up-and-coming "omic" science. J. Natl. Cancer Inst. 96, 732-734 (2004).
6. Lindon, J.C., Holmes, E., Bollard, M.E., Stanley, E.G. & Nicholson, J.K. Metabonomics technologies and their applications in physiological monitoring, Drug safety assessment and disease diagnosis. Biomarkers 9, 1-31 (2004).
7. Weinshilboum, R.M. & Wang, L. Pharmacogenetics and pharmacogenomics: development, Science, And translation. Annu. Rev. Genomics Hum. Genet. 7, 223-245 (2006).
8. Kato, M. & Serretti, A. Review and meta-analysis of antidepressant pharmacogenetic fndings in major depressive disorder. Mol. Psychiatry 15, 473-500 (2010).
9. Mrazek, D.A. et al. SLC6a4 variation and citalopram response. Am. J. Med. Genet. B Neuropsychiatr. Genet. 150B, 341-351 (2009).
10. Serretti, A. & artioli, P. The pharmacogenomics of selective serotonin reuptake inhibitors. Pharmacogenomics J. 4, 233-244 (2004).
11. Garriock, H.A. et al. A genomewide association study of citalopram response in major depressive disorder. Biol. Psychiatry 67, 133-138 (2010).
12. Uher, R. et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am. J. Psychiatry 167, 555-564 (2010).
13. Ising, M. et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch. Gen. Psychiatry 66, 966-975 (2009).
14. Rush, A.J. et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), Clinician rating (QIDS-C), And self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol. Psychiatry 54, 573-583 (2003).
15. Trivedi, M.H. et al.; STaR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STaR*D: implications for clinical practice. Am. J. Psychiatry 163, 28-40 (2006).
16. Iversen, L., Iversen, S., Bloom, F.E. & Roth, R.H. Introduction to Neuropsychopharmacology (Oxford University Press, New york, 2008).
17. Hall, J.C. Glycine. JPEN. J. Parenter. Enteral Nutr. 22, 393-398 (1998).
18. McNeil, J.B., McIntosh, E.M., Taylor, B.V., Zhang, F.R., Tang, S. & Bognar, A.L. Cloning and molecular characterization of three genes, Including two genes encoding serine hydroxymethyltransferases, Whose inactivation is required to render yeast auxotrophic for glycine. J. Biol. Chem. 269, 9155-9165 (1994).
19. Turner, S.R., Ireland, R., Morgan, C. & Rawsthorne, S. Identifcation and localization of multiple forms of serine hydroxymethyltransferase in pea (Pisum sativum) and characterization of a cDNa encoding a mitochondrial isoform. J. Biol. Chem. 267, 13528-13534 (1992).
20. Ichinohe, A. et al. Glycine cleavage system in neurogenic regions. Eur. J. Neurosci. 19, 2365-2370 (2004).
21. Kikuchi, G., Motokawa, Y., Yoshida, T. & Hiraga, K. Glycine cleavage system: reaction mechanism, Physiological signifcance, And hyperglycinemia. Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci. 84, 246-263 (2008).
22. Kaddurah-Daouk, R. & Krishnan, K.R. Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology 34, 173-186 (2009).
23. Quinones, M.P. & Kaddurah-Daouk, R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol. Dis. 35, 165-176 (2009).
24. Yao, J.K. et al. Altered interactions of tryptophan metabolites in frst-episode neuroleptic-naive patients with schizophrenia. Mol. Psychiatry 15, 938-953 (2010).
25. Kaddurah-Daouk, R. et al. Metabolomic mapping of atypical antipsychotic efects in schizophrenia. Mol. Psychiatry 12, 934-945 (2007).
26. Mannelli, P., Patkar, A., Rozen, S., Matson, W., Krishnan, R. & Kaddurah-Daouk, R. Opioid use afects antioxidant activity and purine metabolism: preliminary results. Hum. Psychopharmacol. 24, 666-675 (2009).
27. Patkar, A.A. et al. Alterations in tryptophan and purine metabolism in cocaine addiction: a metabolomic study. Psychopharmacology (Berl.) 206, 479-489 (2009).
28. Altamura, C., Maes, M., Dai, J. & Meltzer, H.Y. Plasma concentrations of excitatory amino acids, Serine, Glycine, Taurine and histidine in major depression. Eur. Neuropsychopharmacol. 5 (suppl.), 71-75 (1995).
29. Sumiyoshi, T., Anil, A.E., Jin, D., Jayathilake, K., Lee, M. & Meltzer, H.Y. Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. Int. J. Neuropsychopharmacol. 7, 1-8 (2004).
30. Mitani, H., Shirayama, Y., Yamada, T., Maeda, K., Ashby, C.R. jr & Kawahara, R. Correlation between plasma levels of glutamate, Alanine and serine with severity of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 30, 1155-1158 (2006).
31. Takayanagi, M. et al. Human glycine decarboxylase gene (GLDC) and its highly conserved processed pseudogene (psiGLDC): their structure and expression, And the identifcation of a large deletion in a family with nonketotic hyperglycinemia. Hum. Genet. 106, 298-305 (2000).
32. Kraft, J.B. et al. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol. Psychiatry 61, 734-742 (2007).
33. McMahon, F.J. et al. Variation in the gene encoding the serotonin 2a receptor is associated with outcome of antidepressant treatment. Am. J. Hum. Genet. 78, 804-814 (2006).
34. Kanno, J. et al. Genomic deletion within GLDC is a major cause of non-ketotic hyperglycinaemia. J. Med. Genet. 44, E69 (2007).
35. Sellner, L., Edkins, E., Greed, L. & Lewis, B. Detection of mutations in the glycine decarboxylase gene in patients with nonketotic hyperglycinaemia. Mol. Genet. Metab. 84, 167-171 (2005).
36. Rang, H.P., Dale, M.M. & Ritter, J.M. Pharmacology, 4th edn. (Churchill Livingstone, Edinburgh, UK, 1999).
37. Storey, J.D. & Tibshirani, R. Statistical signifcance for genomewide studies. Proc. Natl. Acad. Sci. USA 100, 9440-9445 (2003).
38. Ji, Y. et al. Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms. Cancer Res. 68, 5997-6005 (2008).
39. Barrett, J.C., Fry, B., Maller, J. & Daly, M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263-265 (2005).